Ethos Biosciences

Ethos Biosciences designs, develops, and manufactures diagnostics that are accurate, repeatable, and easy to use. Ethos Biosciences was formed as a subsidiary of Ott Scientific in 2018 to drive healthcare innovation by providing diagnostic tools for scientists and practitioners. In November 2018, Ethos Biosciences acquired the Exocell diagnostic operation in Philadelphia from Glycadia Pharmaceuticals. Exocell was founded in 1988 by Dr. Margo Cohen, MD/PhD to explore diagnostic and therapeutic solutions for diabetes. Exocell quickly became a leader in nephrology diagnostics with 15 patents and over research citations. The Exocell brand continues to service the top research, academic, and industrial institutions in the world. Ott Scientific is a family owned and operated group of specialty chemical manufacturing companies with expertise in monomers, polymers, microspheres, and reagents for the pharmaceutical, medical device, and diagnostic industries.